BFRA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Stats
今日成交量	4 951.00
平均成交量	30 523.00
市值	0.00
EPS	$0 ( 2022-04-11 )
Last Dividend	$0.104 ( 2021-02-24 )
Next Dividend	$0 ( N/A )
P/E	-4.35
ATR14	$0.324 (12.13%)

音量相关性

長: 0.02 (neutral)

短: -0.25 (neutral)

Signal:(42.752) Neutral

Biofrontera AG 相关性

10 最正相关
SOHU	0.914
CHB	0.904
NWL	0.904
CSSEP	0.903
TSRI	0.902
AOUT	0.902
HPK	0.9
BMRA	0.897
MODV	0.897
OGI	0.895

10 最负相关
APXI	-0.914
WINV	-0.908
FRSG	-0.907
KAII	-0.906
ZEUS	-0.906
MLAI	-0.905
MATW	-0.904
ALSA	-0.904
MSAC	-0.903
PTOC	-0.903

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Biofrontera AG 相关性 - 货币/商品

0.92
( very strong )

0.00
( neutral )

0.86
( strong )

-0.13
( neutral )

-0.88
( strong negative )

Biofrontera AG 财务报表

Annual	2020
营收:	$30.35M
毛利润:	$26.81M (88.35 %)
EPS:	$-0.467

FY	2020
营收:	$30.35M
毛利润:	$26.81M (88.35 %)
EPS:	$-0.467

FY	2019
营收:	$31.27M
毛利润:	$26.39M (84.41 %)
EPS:	$-0.312

FY	2018
营收:	$21.11M
毛利润:	$16.66M (78.91 %)
EPS:	$-0.389

Financial Reports:

No articles found.

Biofrontera AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Biofrontera AG Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0221	2020-03-18
Last Dividend	$0.104	2021-02-24
Next Dividend	$0	N/A
Payout Date	2021-03-04
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.126	--
Avg. Dividend % Per Year	0.19%	--
Score	0.6	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2025-01-06)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

0.60

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2020	$0.0221	0.22%
2021	$0.104	1.30%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.429	1.500	-8.58	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.231	1.200	-7.70	-9.24	[0 - 0.3]
returnOnEquityTTM	-1.503	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.48	0.800	0.0937	0.0750	[0.8 - 2.5]
cashRatioTTM	1.997	1.500	0.0174	0.0262	[0.2 - 2]
debtRatioTTM	0.423	-1.500	2.94	-4.42	[0 - 0.6]
interestCoverageTTM	-2.47	1.000	-2.03	-2.03	[3 - 30]
operatingCashFlowPerShareTTM	-0.102	2.00	-0.0341	-0.0683	[0 - 30]
freeCashFlowPerShareTTM	-0.130	2.00	-0.0651	-0.130	[0 - 20]
debtEquityRatioTTM	3.24	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.883	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.251	1.000	-7.02	-7.02	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.119	1.000	-1.774	-1.774	[0.2 - 2]
assetTurnoverTTM	0.538	0.800	9.75	7.80	[0.5 - 2]
Total Score				-0.244

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.33	1.000	-0.640	0	[1 - 100]
returnOnEquityTTM	-1.503	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.130	2.00	-0.0434	-0.130	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.102	2.00	-0.0341	-0.0683	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.28	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.0939	1.000	-4.85	0	[0.1 - 0.5]
Total Score				-2.56

Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.